Published in AJR Am J Roentgenol on February 01, 2011
New ultrasound techniques for lymph node evaluation. World J Gastroenterol (2013) 1.12
Nanoparticles for imaging: top or flop? Radiology (2014) 0.97
Staging the axilla in women with breast cancer: the utility of preoperative ultrasound-guided needle biopsy. Cancer Biol Med (2014) 0.87
Contrast enhanced ultrasound of sentinel lymph nodes. J Ultrason (2013) 0.81
Percutaneous removal of sentinel lymph nodes in a swine model using a breast lesion excision system and contrast-enhanced ultrasound. Eur Radiol (2011) 0.79
Microbubble contrast-enhanced ultrasound for sentinel lymph node detection: ready for prime time? AJR Am J Roentgenol (2011) 0.79
Contrast-enhanced ultrasound in oncology. Cancer Imaging (2011) 0.78
Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study. Med Sci Monit (2012) 0.78
Theranostic mRNA-loaded microbubbles in the lymphatics of dogs: implications for drug delivery. Theranostics (2015) 0.78
Optimization of Contrast-to-Tissue Ratio Through Pulse Windowing in Dual-Frequency "Acoustic Angiography" Imaging. Ultrasound Med Biol (2015) 0.77
Is imaging the future of axillary staging in breast cancer? Eur Radiol (2013) 0.77
Intradermal microbubbles and contrast-enhanced ultrasound (CEUS) is a feasible approach for sentinel lymph node identification in early-stage breast cancer. World J Surg Oncol (2015) 0.77
Validation of Contrast Enhanced Ultrasound Technique to Wire Localization of Sentinel Lymph Node in Patients with Early Breast Cancer. Indian J Surg Oncol (2015) 0.75
Contrast - enhanced ultrasound mapping of sentinel lymph nodes in oral tongue cancer - a pilot study. Dentomaxillofac Radiol (2017) 0.75
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med (2008) 4.41
Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A (2004) 4.39
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol (2002) 3.61
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
The CpG island searcher: a new WWW resource. In Silico Biol (2003) 3.42
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell (2007) 3.15
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res (2002) 3.02
DNA methylation: the nuts and bolts of repression. J Cell Physiol (2007) 3.00
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
Epigenetics and microRNAs. Pediatr Res (2007) 2.52
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology (2014) 2.38
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A (2006) 2.25
Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst (2003) 2.22
Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell (2011) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04
Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle (2006) 1.98
Epigenetic changes in cancer. APMIS (2007) 1.96
Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res (2012) 1.95
Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res (2005) 1.94
H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell (2010) 1.85
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther (2005) 1.85
DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet (2011) 1.83
DNA methylation and cellular reprogramming. Trends Cell Biol (2010) 1.77
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res (2002) 1.71
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res (2004) 1.68
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol (2004) 1.68
Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res (2003) 1.62
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
Axillary ultrasound assessment in primary breast cancer: an audit of 653 cases. Breast J (2010) 1.57
Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet (2011) 1.56
Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II. Proc Natl Acad Sci U S A (2006) 1.56
Ring-testing and field-validation of a terrestrial model ecosystem (TME)--an instrument for testing potentially harmful substances: conceptual approach and study design. Ecotoxicology (2004) 1.54
OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. Proc Natl Acad Sci U S A (2011) 1.51
Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genet (2006) 1.48
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol (2006) 1.46
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44
MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly (2009) 1.43
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res (2008) 1.42
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol (2005) 1.41
A new inborn error of glycosylation due to a Cog8 deficiency reveals a critical role for the Cog1-Cog8 interaction in COG complex formation. Hum Mol Genet (2007) 1.40
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res (2007) 1.40
Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res (2007) 1.40
Emergency Department utilisation: a natural experiment. N Z Med J (2009) 1.39
Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol (2011) 1.34
Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res (2002) 1.32
Identification of a new member of the phage shock protein response in Escherichia coli, the phage shock protein G (PspG). J Biol Chem (2004) 1.25
DNA methylation and cancer. Prog Drug Res (2011) 1.24
Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care (2003) 1.22
Chromatin, cancer and drug therapies. Mutat Res (2008) 1.21
Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome. Mol Biol Evol (2003) 1.20
Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer (2005) 1.18
Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood (2011) 1.17
Genome-wide nucleosome map and cytosine methylation levels of an ancient human genome. Genome Res (2013) 1.12
Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res (2005) 1.12
Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci (2005) 1.11
Dementia severity and Lewy bodies affect circadian rhythms in Alzheimer disease. Neurobiol Aging (2004) 1.11
Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res (2013) 1.09
Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet (2012) 1.07
Ring-testing and field-validation of a terrestrial model ecosystem (TME)--an instrument for testing potentially harmful substances: effects of carbendazim on soil microarthropod communities. Ecotoxicology (2004) 1.07
Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One (2010) 1.07
Analysis of individual remodeled nucleosomes reveals decreased histone-DNA contacts created by hSWI/SNF. Nucleic Acids Res (2009) 1.07
Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE). Methods (2002) 1.06
Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction. Methods (2002) 1.06
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res (2008) 1.05
Identification and characterization of alternatively spliced variants of DNA methyltransferase 3a in mammalian cells. Gene (2002) 1.04
Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol (2005) 1.03
A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res (2014) 0.99
Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids (2005) 0.99
Ring-testing and field-validation of a terrestrial model ecosystem (TME)--an instrument for testing potentially harmful substances: effects of carbendazim on organic matter breakdown and soil fauna feeding activity. Ecotoxicology (2004) 0.96
The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle (2009) 0.94
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther (2010) 0.94
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol (2004) 0.94
At the tipping point for epigenetic therapies in cancer. J Clin Invest (2014) 0.94
Ring-testing and field-validation of a terrestrial model ecosystem (TME)--an instrument for testing potentially harmful substances: effects of carbendazim on nematodes. Ecotoxicology (2004) 0.94
Preoperative needle biopsy of sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound in patients with breast cancer. AJR Am J Roentgenol (2012) 0.93